Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

4.3K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.3K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

156
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
156

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases-the PURPLE trial.

ESMO gastrointestinal oncology·2026
Same author

New targets of PET imaging for renal cancer.

Seminars in nuclear medicine·2025
Same author

GMP- compliant formulation and quality control of sodium [<sup>124</sup>I]iodide for oral applications.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2025
Same author

Combining molecular patterns and clinical data for better immune checkpoint inhibitor prediction in metastatic urothelial carcinoma.

Cancer immunology, immunotherapy : CII·2025
Same author

Early-career research education mentoring: a successful program in NeuroHIV and mental health (TRNAMH).

NeuroImmune pharmacology and therapeutics·2025
Same author

Final overall survival and safety analyses of the phase III PSMAfore trial of [<sup>177</sup>Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same journal

Letter from the Editors.

Seminars in nuclear medicine·2026
Same journal

Expanding Horizons: The Role of Kaleidoscope and Relevant Images in Seminars in Nuclear Medicine.

Seminars in nuclear medicine·2026
Same journal

The diagnostic performance and clinical value of [18F]FDG PET/CT in pleural mesothelioma - A systematic review and meta-analysis.

Seminars in nuclear medicine·2026
Same journal

Feasibility of treating neuroendocrine prostate cancer with anti-SSTR radioligands: A systematic review of imaging and treatment studies.

Seminars in nuclear medicine·2026
Same journal

<sup>18</sup>F-FDG -PET/CT in cardiac sarcoidosis: Diagnosis, therapy monitoring, and future directions.

Seminars in nuclear medicine·2026
Same journal

Maximizing diagnostic yield: A systematic review and deep dive into PSMA PET scan protocol variations for prostate cancer.

Seminars in nuclear medicine·2026
See all related articles

Related Experiment Video

Updated: Jul 19, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.0K

Standardized PSMA-PET Imaging of Advanced Prostate Cancer.

R Seifert1, A Gafita2, T Telli1

  • 1Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.

Seminars in Nuclear Medicine
|August 12, 2023
PubMed
Summary
This summary is machine-generated.

Prostate-specific membrane antigen (PSMA)-PET/CT imaging is crucial for advanced prostate cancer. Standardized frameworks like PROMISE and PSMA-RADS help report findings, with PSMA-PET tumor volume showing promise as a biomarker.

More Related Videos

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

278
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K

Related Experiment Videos

Last Updated: Jul 19, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.0K
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

278
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K

Area of Science:

  • Oncology
  • Radiology
  • Nuclear Medicine

Background:

  • Advanced prostate cancer imaging requires standardized methods for treatment selection and efficacy evaluation.
  • Prostate-specific membrane antigen (PSMA)-PET/CT has emerged as the standard for advanced prostate cancer imaging.
  • Standardized reporting frameworks like PROMISE and PSMA-RADS are essential for consistent PSMA-PET interpretation.

Purpose of the Study:

  • To discuss recent evidence on PSMA-PET derived tumor volume as a biomarker for outcome prognostication.
  • To review and discuss established and emerging frameworks for reporting and response assessment in PSMA-PET imaging.
  • To highlight the clinical relevance of PSMA-PET biomarkers for patient management.

Main Methods:

  • Review of recent evidence on PSMA-PET derived tumor volume and its prognostic value.
  • Discussion of standardized reporting frameworks: PROMISE and PSMA-RADS.
  • Explanation and discussion of response assessment frameworks: PSMA-PET Progression (PPP) criteria and Response Evaluation Criteria in PSMA (RECIP).

Main Results:

  • PSMA-PET derived tumor volume, particularly when quantified per-organ system (PROMISE framework), is a valuable biomarker for outcome prognostication.
  • Changes in PSMA-PET derived tumor volume show promise for assessing treatment response.
  • Limitations exist, including potential misinterpretation due to decreasing PSMA expression and suitability for limited disease.

Conclusions:

  • Standardized frameworks are crucial for objective reporting and response assessment in PSMA-PET imaging for advanced prostate cancer.
  • PSMA-PET derived tumor volume and its changes are important biomarkers for clinical management and outcome prediction.
  • Emerging criteria like PPP and RECIP offer optimized response assessment for different disease phenotypes.